Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tianjin TEDA Biomedical Engineering Co (FRA:TJJ) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Tianjin TEDA Biomedical Engineering Co Receivables Turnover Related Terms
Tianjin TEDA Biomedical Engineering Co Receivables Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tianjin TEDA Biomedical Engineering Co Receivables Turnover Chart
Tianjin TEDA Biomedical Engineering Co Annual Data
FRA:TJJ vs CTVA, CF, MOS: Receivables Turnover Comparison
For the Agricultural Inputs subindustry, Tianjin TEDA Biomedical Engineering Co's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tianjin TEDA Biomedical Engineering Co Receivables Turnover vs Agriculture Industry
For the Agriculture industry and Basic Materials sector, Tianjin TEDA Biomedical Engineering Co's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Tianjin TEDA Biomedical Engineering Co's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tianjin TEDA Biomedical Engineering Co (FRA:TJJ) has a Receivables Turnover of 12.18 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Tianjin TEDA Biomedical Engineering Co and its competitors. According to the industry distribution chart, Tianjin TEDA Biomedical Engineering Co ranks #30 out of 245 companies in the Agriculture industry, placing it in the top 12.2%.
Is Tianjin TEDA Biomedical Engineering Co's Receivables Turnover too high?
Tianjin TEDA Biomedical Engineering Co's current Receivables Turnover is 12.18. The Agriculture industry median Receivables Turnover is 5.59. Tianjin TEDA Biomedical Engineering Co's value of 12.18 is 117.9% above this industry median. Based on the distribution chart, Tianjin TEDA Biomedical Engineering Co ranks #30 out of 245 companies in the Agriculture industry, which is in the top quartile — a strong position relative to peers. Overall, Tianjin TEDA Biomedical Engineering Co has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tianjin TEDA Biomedical Engineering Co's Receivables Turnover compare to CTVA and CF?
According to the Agriculture industry distribution chart, Tianjin TEDA Biomedical Engineering Co ranks #30 out of 245 companies for Receivables Turnover. This places Tianjin TEDA Biomedical Engineering Co in the top 12% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.59. Tianjin TEDA Biomedical Engineering Co's value of 12.18 is 117.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for an Agriculture company?
The median Receivables Turnover among Agriculture companies is 5.59, based on 245 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tianjin TEDA Biomedical Engineering Co's current Receivables Turnover of 12.18 is 117.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Tianjin TEDA Biomedical Engineering Co and its competitors. For the Agriculture industry, the median Receivables Turnover is 5.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tianjin TEDA Biomedical Engineering Co's current Receivables Turnover is 12.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tianjin TEDA Biomedical Engineering Co stock overvalued right now?
Based on GuruFocus' analysis, Tianjin TEDA Biomedical Engineering Co (FRA:TJJ) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.01, compared to a current price of €0.02 — trading 115% above its estimated fair value. The current Receivables Turnover is 12.18 and 117.9% above the Agriculture industry median of 5.59. Tianjin TEDA Biomedical Engineering Co's overall GF Score™ is 28/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Tianjin TEDA Biomedical Engineering Co (FRA:TJJ), the current Receivables Turnover is 12.18 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tianjin TEDA Biomedical Engineering Co (FRA:TJJ) Overvalued in 2026?
Based on GuruFocus' analysis, Tianjin TEDA Biomedical Engineering Co stock appears to be overvalued.
The current stock price of €0.02 is trading 115% above its estimated GF Value™ of €0.01.
GuruFocus considers Tianjin TEDA Biomedical Engineering Co to be Significantly Overvalued.
Key valuation signals for FRA:TJJ:
Receivables Turnover: 12.18
GF Value™: €0.01 vs. price of €0.02 (115% above fair value)
Industry Position: 117.9% above the Agriculture median (#30 of 245)
No single metric tells the full story. See the FRA:TJJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tianjin TEDA Biomedical Engineering Co Ltd principally engages in manufacture and sale of biological compound fertiliser products and elderly care and health care services and related products. The group is principally engaged in manufacturing and selling biological compound fertilisers, AI health & elderly care products and services. It operates in two segments namely; fertilisers products; and AI health & elderly care products and services. The company generates a majority of its revenue from the Fertilisers products segment. The People's Republic of China is the primary geographical market for the company.
28GF Score
Get the complete analysis for FRA:TJJ
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:TJJ has been successfully added to your 
